Pharmacotherapy of cryptococcosis (Q37587230)

21 August 2017

1 reference

title

Pharmacotherapy of cryptococcosis (English)

1 reference

21 August 2017

0 references

1 reference

Michele Ritter

1

1 reference

21 August 2017

David L Goldman

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

Expert Opinion on Pharmacotherapy

21 August 2017

published in

1 reference

21 August 2017

volume

10

1 reference

21 August 2017

issue

15

1 reference

21 August 2017

page(s)

2433-2443

1 reference

The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Do major species concepts support one, two or more species within Cryptococcus neoformans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997-2002): epidemiology, microbiology and histopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Serologic evidence for Cryptococcus neoformans infection in early childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Disseminated cryptococcal infection and anti-tumor necrosis factor-alpha treatment for refractory sarcoidosis: an expected association?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

The effect of amphotericin B on the K-channel activity of MDCK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Mortality and costs of acute renal failure associated with amphotericin B therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Study of renal safety in amphotericin B lipid complex-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Efficacy of a short-term amphotericin B + flucytosine combination therapy followed by itraconazole monotherapy in acute and chronic AIDS-associated cryptococcosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Voriconazole for cryptococcal meningitis in children with leukemia or receiving allogeneic hemopoietic stem cell transplant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Prognostic factors in cryptococcal meningitis. A study in 111 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal Meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

In Vitro Studies with Combinations of 5-Fluorocytosine and Amphotericin B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Major role for amphotericin B-flucytosine combination in severe cryptococcosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Antifungal management practices and evolution of infection in organ transplant recipients with cryptococcus neoformans infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Cryptococcosis, with Emphasis on the Significance of Isolation of Cryptococcus neoformans from the Respiratory Tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Pulmonary cryptococcosis in patients without HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Pulmonary cryptococcosis in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Pulmonary cryptococcosis: localized and disseminated infections in 27 patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Pulmonary resection for localized lesions of cryptococcosis (torulosis): a review of eight cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

21 January 2018

Cryptococcal Cellulitis

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

A case of primary cutaneous cryptococcosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. California Collaborative Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Effects of antifungal agents and gamma interferon on macrophage cytotoxicity for fungi and tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

In vivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

The gamma interferon receptor is required for the protective pulmonary inflammatory response to Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Protective efficacy of antigenic fractions in mouse models of cryptococcosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

Fungal Burden, Early Fungicidal Activity, and Outcome in Cryptococcal Meningitis in Antiretroviral-Naive or Antiretroviral-Experienced Patients Treated with Amphotericin B or Fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903200642

10.1517/14656560903200642

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference